Low Density Lipoprotein (LDL) News and Research

RSS

Five tips to lower cholesterol

An estimated 102 million Americans have cholesterol levels that are considered borderline high-risk. This staggering fact makes lowering cholesterol one of the most imperative things to do to promote overall heart health. Unfortunately, too few people understand the essential steps in reaching this goal.

9 Feb 2011

How cocoa in chocolate reduces risk of heart disease

In time for the chocolate-giving and chocolate-noshing fest on Valentine's Day, scientists are reporting discovery of how this treat boosts the body's production of high-density lipoprotein cholesterol (HDL) - the "good" form of cholesterol that protects against heart disease.

8 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Study: Pistachios may help reduce risk of heart disease

It's no coincidence that National Pistachio Day – February 26, 2011 – occurs during American Heart Month. Heart disease remains the leading cause of death in America, and promising nutrition research shows that pistachios are a heart healthy snack choice. In honor of American Heart Month, TheGreenNut.org is offering simple tips encouraging all Americans to go green for a healthy heart this February.

4 Feb 2011

New research: Antioxidants in pecans may prevent development of various diseases

A new research study from Loma Linda University demonstrates that naturally occurring antioxidants in pecans may help contribute to heart health and disease prevention; the results are published in the January 2011 issue of The Journal of Nutrition.

2 Feb 2011

Soy protein lowers total cholesterol and non-HDL: New study

Soy protein's ability to lower total and LDL cholesterol has been extensively studied, but the mechanism whereby soy protein lowers cholesterol remains unresolved. A new study published in the Journal of Clinical Lipidology last month shows that soy protein lowers total cholesterol and non-HDL cholesterol significantly more than milk protein in patients with moderately high cholesterol levels.

18 Jan 2011

14 foods that deliver research-documented benefits to health

With the start of a new year, many of us resolve to better our habits by trying to incorporate more nutritious foods into our diets. An article in the January issue of Food Technology magazine lists 14 foods that deliver research-documented benefits to health.

14 Jan 2011

Teenagers who consume excess sugar may face risk of developing heart disease

Teenagers who consume a lot of added sugars in soft drinks and foods may have poor cholesterol profiles — which may possibly lead to heart disease in adulthood, according to first-of-its-kind research reported in Circulation: Journal of the American Heart Association.

11 Jan 2011

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate.

7 Jan 2011

Positive topline results from ZGN-433 Phase 1b study in obesity patients

Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.

6 Jan 2011

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.

6 Jan 2011

Lifestyle changes between childhood and adulthood linked to high-risk cholesterol levels

Lifestyle changes between childhood and adulthood appear associated with whether an individual will maintain, improve or develop high-risk cholesterol levels, according to a report in the January issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

4 Jan 2011

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. Hypertriglyceridemia, a condition characterized by elevated levels of triglycerides, is an independent risk factor for cardiovascular disease and is a component of numerous cardiovascular and metabolic diseases, including metabolic syndrome.

21 Dec 2010

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.

16 Dec 2010

Almonds can help treat, prevent type 2 diabetes and cardiovascular disease

With nearly 16 million Americans living today with pre-diabetes, a condition that is the precursor to type 2 diabetes, and half of all Americans expected to have some form of diabetes by the year 2020, healthy eating is more important than ever. But here is some good news: a recent scientific study shows that incorporating almonds into your diet can help treat and possibly prevent type 2 diabetes, as well as cardiovascular disease.

15 Dec 2010

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested

10 Dec 2010

EFSA publishes positive opinion on disease risk reduction health claim for oat beta-glucan

A scientific panel of the European Food Safety Authority (EFSA) published its positive opinion on a disease risk reduction health claim dossier for oat beta-glucan on 8. December 2010, following an application from CreaNutrition AG submitted pursuant to Article 14 of the EC regulation on nutrition and health claims.

9 Dec 2010

Smoking is common among young adults and children with diabetes, raises risk of heart disease

Cigarette smoking is widespread among children and young adults with diabetes yet few health care providers are counseling children and young adults with diabetes to not smoke or stop smoking, according to a new report from the SEARCH Study Group, published online in the Journal of Pediatrics.

7 Dec 2010

Experts reach consensus on beneficial effects of Soy

According to the December 2010 Journal of Nutrition Supplement titled, "Soy Summit: Exploration of the Nutrition and Health Effects of Whole Soy," consensus has been reached among leading soy science experts surrounding three main areas of debate: soy and women's health, soy and heart health, and soy and overall nutrient adequacy. Leading soy experts agree that including soyfoods in a balanced diet will have beneficial effects and improve nutrient intake among the U.S. population.

3 Dec 2010

Resverlogix files new patent for dosing combinations of RVX-208, statin therapeutics

Resverlogix Corp. is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed ASSERT Phase 2 clinical trial.

30 Nov 2010